The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

In a groundbreaking new study, the active ingredient in Ozempic was found to be so effective at treating arthritis that ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Looking to drop those stubborn pounds? The weight loss world is buzzing about a game-changing medication that's helping ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.